| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO | Vp-finance
1 company
Kerri-Ann Millar last filed a Form 4 in March 2025, as Chief Financial Officer at CUE. Kerri-Ann Millar's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 14,311 shares of CUE. The CUE filings lean toward selling, a net 251 shares.
Kerri-Ann Millar has 14 Form 4 filings on record from July 2018 to March 2025, all as Chief Financial Officer at Cue Biopharma (CUE), 2018–2025.
The 22 reported transactions were 13 option or other derivative awards, 4 option exercises, 3 tax withholdings and 1 open-market sale, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $8K and 1 sale worth about $18K.
The only open-market purchase was 1,000 shares of CUE at an average $8.48 on August 29, 2018, about $8K.
The only open-market sale was 1,251 shares of CUE at an average $14.21 on October 1, 2021, about $18K. Twelve months later CUE was down 85%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.